Investor Perception
Cardiol Therapeutics is positioned with a late-stage lead asset, a number of orphan indications, sturdy scientific proof-of-concept information, and a differentiated non-immunosuppressive strategy to inflammatory coronary heart illness. The corporate’s 2025–2026 catalysts – MAVERIC Section III enrollment progress, full ARCHER information, and CRD-38 scientific initiation – are key worth drivers in giant and underserved cardiovascular markets.
Overview
Cardiol Therapeutics Inc. (NASDAQ:CRDL,TSX:CRDL) is a clinical-stage life sciences firm targeted on the analysis, growth, and commercialization of progressive anti-inflammatory and anti-fibrotic therapies for the remedy of coronary heart illness. The corporate’s applications goal severe, typically life-threatening cardiovascular situations for which there are restricted or no permitted remedies, together with recurrent pericarditis, acute myocarditis, and coronary heart failure.
Cardiol’s therapeutic strategy facilities on modulating inflammasome pathway activation—a central driver of irritation and fibrosis within the coronary heart. That is achieved via pharmaceutically manufactured cannabidiol formulations developed below cGMP requirements. Cannabidiol has been proven in preclinical and scientific research to down-regulate inflammatory mediators (e.g., IL-1, IL-6) and protect cardiac construction and performance, providing the potential for disease-modifying, non-immunosuppressive remedy choices.
The corporate’s lead oral drug candidate, CardiolRx™, is in late-stage scientific growth:
Cardiol can also be advancing CRD-38, a proprietary subcutaneous cannabidiol formulation for coronary heart failure. IND-enabling research are underway following compelling preclinical outcomes exhibiting cardioprotection via preservation of mitochondrial operate and prevention of cardiac transforming.
What it’s: A pivotal scientific program testing CardiolRx™ in sufferers with recurrent pericarditis, a painful and debilitating irritation of the membrane across the coronary heart that always returns regardless of prior remedies. The situation could cause extreme chest ache, shortness of breath, and repeated hospitalizations.
Why it issues: Present third-line remedy is dear, immunosuppressive and related to a excessive recurrence charge after discontinuation. CardiolRx™ affords the potential for a non-immunosuppressive, disease-modifying possibility.
Standing:
- Accomplished MAvERIC-Pilot Section II: Fast and sturdy reductions in ache and irritation sustained over 26 weeks; majority of sufferers recurrence-free throughout extension.
- Section III MAVERIC trial: Multinational, double-blind, placebo-controlled examine enrolling 110 high-risk sufferers throughout ~20 websites in North America and Europe. Major endpoint: recurrence-free charge at 24 weeks after IL-1 blocker discontinuation.
What it’s: A world Section II trial evaluating CardiolRx™ in acute myocarditis, an inflammatory coronary heart muscle illness and a serious explanation for sudden cardiac loss of life in folks below 35.
Why it issues: There are not any FDA- or EMA-approved medicine for acute myocarditis. Present care is supportive, and lots of sufferers develop power coronary heart issues.
Standing:
- Enrolled 109 sufferers at 34 websites throughout 5 international locations; accomplished in This fall 2024.
- Topline outcomes (Q3 2025) confirmed notable enhancements in coronary heart muscle well being (extracellular quantity, LV mass) and confirmed security/tolerability.
- Full outcomes to be introduced at a scientific assembly in H2 2025.
Coronary heart Failure Program – CRD-38
What it’s: Improvement of a subcutaneous cannabidiol formulation for coronary heart failure, together with coronary heart failure with preserved ejection fraction (HFpEF), a situation with restricted remedy choices and excessive mortality.
Why it issues: Coronary heart failure impacts over 64 million folks globally, with excessive hospitalization and loss of life charges; irritation and fibrosis play key roles in illness development.
Standing:
- IND-enabling research underway; Section I trial deliberate after regulatory submission.
- Preclinical analysis exhibits CRD-38 protects coronary heart muscle cells, preserves mitochondrial operate, and prevents transforming and irritation.
Administration Workforce
David Elsley – President, Chief Govt Officer, and Director
David Elsley is the founder and former president and CEO of Vasogen. He has greater than 30 years’ expertise creating, financing, and managing company growth of life sciences corporations.
Dr. Andrew Hamer – Chief Medical Officer and Head of Analysis and Improvement
Dr. Andrew Hamer has an MBChB diploma. Hamer is the previous government director at Amgen, answerable for main world growth of Repatha®. Hamer is the previous chief heart specialist at Nelson Hospital, New Zealand. He has over 19 years of expertise working towards cardiology and inside medication.
Chris Waddick – Chief Monetary Officer and Director
Chris Waddick has an MBA diploma, is a chartered skilled accountant, and is an authorized administration accountant. Waddick has over 30 years of expertise in monetary and government roles within the biotechnology and vitality industries. Waddick is the previous chief monetary officer and chief working officer of Vasogen Inc.
Bernard Lim – Chief Working Officer
Bernard Lim has over 30 years of expertise within the life sciences trade, spanning biotechnology, diagnostics, medical units, and high-technology corporations. Lim is the founder and CEO of a extremely profitable drug supply firm that he led from analysis and growth via to commercialization, and facilitated its eventual acquisition by Eli Lily. Lim is a chartered engineer per UK requirements and is a member of the Establishment of Engineering and Know-how.
Andrea B. Parker – Senior Director of Medical Operations
Dr. Andrea Parker is the previous chief scientific officer at Peter Munk Cardiac Middle, College Well being Community. Parker is a scientific epidemiologist with greater than 30 years’ expertise in scientific trials design, administration, and execution in trade and educational settings.
John A. Geddes – Vice-President, Company Improvement
John Geddes has over 25 years of expertise within the healthcare trade, comprising roles inside pharmaceutical, biotechnology, scientific diagnostics, and life science analysis know-how corporations. Geddes has an MBA diploma and is the previous company senior director of enterprise growth at Luminex Company, a DiaSorin Firm.
Anne Tomalin – Director of Regulatory and High quality
Anne Tomalin is the founding father of CanReg and TPIreg, regulatory corporations beforehand offered to Optum Perception and Innomar Methods, respectively. Tomalin is an skilled in regulatory affairs in Canada, the USA, and Europe.
Board of Administrators
Guillermo Torre-Amione – Chairman
Guillermo Torre-Amione is the president of TecSalud educational medical heart and faculty of the Instituto Tecnológico y de Estudios Superiores de Monterrey (ITESM), Mexico. Torre-Amione is the previous director of Cardiac Transplantation on the Houston Methodist DeBakey Coronary heart & Vascular Middle.
Jennifer M. Chao – Director
Jennifer M. Chao has over 25 years of expertise within the biotech and life sciences industries targeted totally on finance and company technique. Chao is managing companion of CoreStrategies Administration, an organization she based in 2008 to offer transformational company and monetary methods to biotech/life science corporations for maximizing core valuation.
Peter Pekos – Director
Founding father of Dalton Pharma, Peter Pekos has broad expertise in analysis, growth, and commercialization of prescription drugs, merchandise, and providers.
Colin Stott – Director
Colin Stott has over 30 years of expertise in pre-clinical and scientific growth, with particular experience within the growth of cannabinoid-based medicines. Stott is the chief working officer of Alterola Biotech Inc. and the previous scientific affairs director, worldwide, and analysis and growth operations director for GW Prescription drugs, a world chief within the growth of cannabinoid therapeutics.
Teri Loxam – Director
Teri Loxam has over 25 years of expertise within the pharmaceutical, life sciences and TMT industries with various roles spanning technique, investor relations, finance and communications. Loxam is chief monetary officer of Compass Pathways plc (Nasdaq:CMPS), a biotechnology firm devoted to accelerating affected person entry to evidence-based innovation in psychological well being.
Timothy Garnett – Director
Timothy Garnett is the chair of Ophirex and director of Maplight Therapeutics. He’s a pharmaceutical trade government with over 30 years’ expertise, together with twenty years at Eli Lilly and Firm, the place he served as Chief Medical Officer from 2008 till his retirement in 2021. Throughout his tenure at Eli Lilly, he led the profitable growth of therapeutics in ladies’s well being, endocrinology, and neuroscience, leading to a number of industrial launches globally.
Scientific Advisory Board
Dr. Paul Ridker is director of the Middle for Cardiovascular Illness Prevention, a translational analysis unit at Brigham and Girls’s Hospital in Boston (BWH). A cardiovascular medication specialist, he’s additionally the Eugene Braunwald Professor of Drugs at Harvard Faculty of Drugs (HSM). Ridker acquired his medical diploma from HSM after which accomplished an inside medication residency and a cardiology fellowship at BWH. He’s board licensed in inside medication. Ridker’s scientific pursuits embody coronary artery illness and the underlying causes and prevention of atherosclerotic illness. He’s the creator of over 900 peer-reviewed publications and opinions, 64 ebook chapters, and 6 textbooks associated to cardiovascular medication.
Dr. Bruce McManus is a professor emeritus of the Division of Pathology and Laboratory Drugs on the College of British Columbia. He has served as CEO of the Middle of Excellence for Prevention of Organ Failure (PROOF Middle), director of the UBC Middle for Coronary heart and Lung Innovation, and scientific director of the Institute of Circulatory and Respiratory Well being, CIHR. McManus acquired BA and MD levels from the College of Saskatchewan, an MSc from Pennsylvania State College, and a PhD from the College of Toledo. McManus pursued post-doctoral fellowships on the College of California, Santa Barbara in environmental physiology and on the Nationwide Coronary heart, Lung, and Blood Institute in Bethesda. McManus served as MD in cardiovascular and pulmonary pathology, and accomplished residency coaching on the Peter Bent Brigham Hospital, Harvard College, in Inside Drugs and Pathology.
Dr. Joseph Hill is a professor of inside medication and molecular biology, chief of cardiology at UT Southwestern Medical Middle, in Dallas, and is the director of the Harry S. Moss Coronary heart Middle. Hill holds each the James T. Willerson, MD, distinguished chair in cardiovascular ailments, and the Frank M. Ryburn Jr. Chair in Coronary heart Analysis. He graduated from Duke College with an MD and a PhD in 1987. Hill’s PhD dissertation analysis was within the subject of cardiac ion channel biophysics. He then labored for 5 years as a postdoctoral fellow on the Institut Pasteur in Paris, finding out central and peripheral nicotinic receptors. He subsequent accomplished an inside medication internship and residency, in addition to a scientific cardiology fellowship, on the Brigham and Girls’s Hospital, Harvard Medical Faculty.
